配方奶粉试验的实施与报告:系统综述
该系统综述检索2006至2020年Medline、Embase和CENTRAL数据库,纳入比较至少两种配方奶粉产品的儿童干预试验。共识别307项试验,其中仅24%前瞻性注册;2015年后发表的125项详细分析试验中,仅14%独立于配方奶粉公司,80%存在高偏倚风险,主要因不当排除和选择性报告。汇总标准化均数差为0.51,校正漏斗图不对称后降至0.19,提示发表偏倚。
要点
- 配方奶粉试验多数缺乏独立性,仅14%独立于企业
- 80%近期试验存在高偏倚风险,主因不当排除和选择性报告
- 汇总效应校正不对称后明显减小,提示发表偏倚
核心结论
- 配方奶粉试验缺乏独立性和透明度,已发表结局受选择性报告偏倚影响。
研究设计与样本
- 系统综述检索Medline、Embase和CENTRAL数据库2006年1月1日至2020年12月31日。
- 纳入比较至少两种配方奶粉产品的儿童(小于三岁)干预试验,排除人乳或母乳强化剂试验。
主要发现
- 近期发表的125项试验中,17项(14%)独立于配方奶粉公司,26项(21%)前瞻性注册且有明确目的和主要结局,11项(9%)共享前瞻性方案。
- 近期试验中偏倚风险低者5项(4%),高者100项(80%),主要因不当排除和选择性报告。
- 68项近期优效性试验的汇总标准化均数差为0.51(范围-0.43至3.29),漏斗图不对称(Egger检验P<0.001),校正后降至0.19。
- 86项(69%)试验的主要结局被作者报告为有利,115项(92%)摘要结论为有利。
- 部分母乳喂养婴儿的38项试验中仅1项(3%)报告充分支持母乳喂养;非母乳喂养婴儿的87项试验中14项(16%)确认入组前不母乳喂养决定已牢固确立。
关键数值与推荐
- 系统综述注册号PROSPERO 2018 CRD42018091928。
- 偏倚风险采用Cochrane risk of bias version 2.0评估,母乳喂养 undermining 风险依据已发表共识指南评估。
临床怎么用
- 解读配方奶粉试验时需关注独立性、前瞻性注册和选择性报告偏倚。
- 临床决策应谨慎对待企业资助或未注册的配方奶粉试验结论。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To systematically review the conduct and reporting of formula trials. DESIGN: Systematic review. DATA SOURCES: Medline, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from 1 January 2006 to 31 December 2020. REVIEW METHODS: Intervention trials comparing at least two formula products in children less than three years of age were included, but not trials of human breast milk or fortifiers of breast milk. Data were extracted in duplicate and primary outcome data were synthesised for meta-analysis with a random effects model weighted by the inverse variance method. Risk of bias was evaluated with Cochrane risk of bias version 2.0, and risk of undermining breastfeeding was evaluated according to published consensus guidance. Primary outcomes of the trials included in the systematic review were identified from clinical trial registries, protocols, or trial publications. RESULTS: 22 201 titles were screened and 307 trials were identified that were published between 2006 and 2020, of which 73 (24%) trials in 13 197 children were prospectively registered. Another 111 unpublished but registered trials in 17 411 children were identified. Detailed analysis was undertaken for 125 trials (23 757 children) published since 2015. Seventeen (14%) of these recently published trials were conducted independently of formula companies, 26 (21%) were prospectively registered with a clear aim and primary outcome, and authors or sponsors shared prospective protocols for 11 (9%) trials. Risk of bias was low in five (4%) and high in 100 (80%) recently published trials, mainly because of inappropriate exclusions from analysis and selective reporting. For 68 recently published superiority trials, a pooled standardised mean difference of 0.51 (range -0.43 to 3.29) was calculated with an asymmetrical funnel plot (Egger's test P<0.001), which reduced to 0.19 after correction for asymmetry. Primary outcomes were reported by authors as favourable in 86 (69%) trials, and 115 (92%) abstract conclusions were favourable. One of 38 (3%) trials in partially breastfed infants reported adequate support for breastfeeding and 14 of 87 (16%) trials in non-breastfed infants confirmed the decision not to breastfeed was firmly established before enrolment in the trial. CONCLUSIONS: The results show that formula trials lack independence or transparency, and published outcomes are biased by selective reporting. SYSTEMATIC REVIEW REGISTRATION: PROSPERO 2018 CRD42018091928.
引用
- Helfer B, Leonardi-Bee J, Mundell A, et al. Conduct and reporting of formula milk trials: systematic review. BMJ. 2021. PMID: 34645600. doi:10.1136/bmj.n2202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。